» Articles » PMID: 22350004

Histological and Clinical Characteristics of Malignant Giant Cell Tumor of Bone

Overview
Journal Virchows Arch
Date 2012 Feb 22
PMID 22350004
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant giant cell tumors of bone (MGCTB) are rare, and the diagnosis can be difficult due to the occurrence of a variety of malignant tumors containing giant cells. To better understand its clinicopathological features, we have reviewed our experience with 17 cases of MGCTB. Five cases were primary malignant giant cell tumor of bone (PMGCTB), and 12 cases were giant cell tumors of bone initially diagnosed as benign but malignant in a recurrent lesion (secondary MGCTB, SMGCTB). The patients included six women and 11 men (age ranged from 17 to 52 years; mean, 30.5 years). The tumor arose in the femur (six cases), the tibia (seven cases), the humerus (three cases), and the fibula (one case). Microscopically, PMGCTB showed both conventional giant cell tumor and malignant sarcoma features. SMGCTB were initially diagnosed as conventional giant cell tumor of bone, the recurrent lesion showing malignant features. Histologically, the malignant components included osteosarcoma (11 cases), undifferentiated high-grade pleomorphic sarcoma (two cases), and fibrosarcoma (four cases). SMGCTB cases showed strong expression of p53. Follow-up information revealed that four patients died of lung metastasis, two patients are alive with lung metastases, and 11 patients are alive without tumor. MGCTB should be considered as a high-grade sarcoma. It must be distinguished from GCTB and other malignant tumors containing giant cells. p53 might play a role in the malignant transformation of GCTB.

Citing Articles

Management and surveillance of metastatic giant cell tumour of bone.

Fellows D, Kotowska J, Stevenson T, Brown J, Orosz Z, Siddiqi A Pathol Oncol Res. 2025; 31:1611916.

PMID: 40046036 PMC: 11879744. DOI: 10.3389/pore.2025.1611916.


A Case of Fibrosarcoma Arising in Giant Cell Tumor of Bone: a Rare Entity.

Singh A, Pujani M, Singh K, Yadav A, Prasad B, Agarwal P Indian J Surg Oncol. 2024; 15(Suppl 1):162-166.

PMID: 38545598 PMC: 10963346. DOI: 10.1007/s13193-023-01806-9.


Current therapies and future prospective for locally aggressive mesenchymal tumors.

Maleddu A, Zhu J, Clay M, Wilky B Front Oncol. 2023; 13:1160239.

PMID: 37546427 PMC: 10401592. DOI: 10.3389/fonc.2023.1160239.


Genetic characterization of a novel organoid from human malignant giant-cell tumor.

Suzuki R, Wakamatsu T, Yoshida K, Matsuoka Y, Takami H, Nakai S J Bone Oncol. 2023; 41:100486.

PMID: 37260767 PMC: 10227374. DOI: 10.1016/j.jbo.2023.100486.


Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.

Vari S, Riva F, Onesti C, Cosimati A, Renna D, Biagini R Int J Mol Sci. 2022; 23(18).

PMID: 36142631 PMC: 9506170. DOI: 10.3390/ijms231810721.


References
1.
Gitelis S, Wang J, Quast M, SCHAJOWICZ F, Templeton A . Recurrence of a giant-cell tumor with malignant transformation to a fibrosarcoma twenty-five years after primary treatment. A case report. J Bone Joint Surg Am. 1989; 71(5):757-61. View

2.
Boriani S, Sudanese A, Baldini N, Picci P . Sarcomatous degeneration of giant cell tumours. Ital J Orthop Traumatol. 1986; 12(2):191-9. View

3.
Forsyth R, De Boeck G, Bekaert S, De Meyer T, Taminiau A, Uyttendaele D . Telomere biology in giant cell tumour of bone. J Pathol. 2008; 214(5):555-63. DOI: 10.1002/path.2301. View

4.
HUTTER R, WORCESTER Jr J, FRANCIS K, FOOTE FW Jr STEWART F . Benign and malignant giant cell tumors of bone. A clinicopathological analysis of the natural history of the disease. Cancer. 1962; 15:653-90. DOI: 10.1002/1097-0142(196207/08)15:4<653::aid-cncr2820150402>3.0.co;2-m. View

5.
Alberghini M, Kliskey K, Krenacs T, Picci P, Kindblom L, Forsyth R . Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch. 2009; 456(1):97-103. DOI: 10.1007/s00428-009-0863-2. View